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A B S T R A C T
We report herein a case of bacteremic ascitic ﬂuid infection in a liver transplant patient caused by a strain
of Yersinia pseudotuberculosis serogroup I that lost the yersiniabactin core. The patient’s outcome was
favorable after a combined therapy with a third-generation cephalosporin and gentamicin.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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A 49-year-old man was admitted to our hepatology intensive
care unit on January 2013 for confusion, hyperthermia, and
headaches with no stiff neck, persisting for four days. Three years
earlier, the patient underwent liver transplantation because of
alcohol and hepatitis C virus (HCV) cirrhosis. Following transplan-
tation, he had a recurrence of HCV infection. He had travelled in
Algeria and in Guadeloupe in 2011 and 2012, respectively. He
reported no animal exposure except to his domestic cat. The patient
had not beneﬁted from prolonged antibiotic prophylaxis upon
admission. On admission, physical examination revealed no speciﬁc* Corresponding author. Laboratoire de Bacte´riologie-Hygie`ne. Groupe Hospita-
lier Pitie´-Salpeˆtrie`re; 47-83 bd de l’Hoˆpital; 75651 Paris cedex 13.
Tel.: +33142162070; fax: +33142162072.
E-mail address: aurelie.renvoise@gmail.com (A. Renvoise´).
http://dx.doi.org/10.1016/j.ijid.2015.03.019
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).abnormalities. Blood analysis recovered a low white blood cell
count of 3 G/L (N: 4-10 G/L), elevated liver enzymes (aspartate
aminotransferase 240 U/L (N: 10-45 U/L), alkaline phosphatase
323 U/L (N: 35-120 U/L), gamma glutamyl transferase 861 U/L (7-55
U/L)), ferritinemia = 4111 mg/L, and triglyceridemia = 4.36 mmol/L.
Blood (7 samples), cerebrospinal ﬂuid and urine collected upon
admission were culture-negative during the ﬁrst three days of
hospitalization, and the patient was not receiving any antibiotic
(Table 1). On day (D) 5, a brain magnetic resonance imaging found a
ﬁlled maxillary sinus, and a treatment with amoxicillin/clavulanic
acid was initiated (Table 1). On D6, the whole body scan recovered
an importantascitic ﬂuid, which had not been detected upon clinical
examination, and later explained by transjugular biopsy showing
recurrence of cirrhosis. A simultaneous puncture of the ascitic ﬂuid
showed 600/mm3 leukocytes with 20% of polymorphonuclear
neutrophils, but both cultures incubated at 37 8C and ascitic ﬂuid
sample seeded into blood culture bottles were negative. However,
ciproﬂoxacin was added to amoxicillin/clavulanic acid sinceciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Schematic chronological representation of antibiotic treatment, outcome, and bacteriological samples
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which met the criteria for an ascitic ﬂuid infection (Table 1). On D7,
i.e. 24 hours after the initiation of ciproﬂoxacin treatment, a second
puncture of the ascitic ﬂuid showed a decrease of leukocytes count
to 280/mm3 with 27% of polymorphonuclear neutrophils; this
ascitic ﬂuid seeded into blood culture bottles and also two blood
samples seeded in anaerobic blood culture bottles (sampled on D4
and D5), grew Gram negative rods at 37 8C (Table 1). The
identiﬁcation of the strain using API 1 20E and 32GN systems
(Biome´rieux, Marcy l’Etoile, France) was unambiguously Yersinia
pseudotuberculosis. Bacterial identiﬁcation of the strain was
performed by 16S rRNA sequencing as previously described;1 we
obtained a 470 bp sequence, which was found to differ at only
1 nucleotide position from that of Y. pseudotuberculosis and Y. pestis
(GenBank CP002956 and CP001048, respectively), consisting of
99.8% similarity. We used protein proﬁling through the use of
matrix-assisted laser desorption/ionization time-of-ﬂight mass
spectrometry (Bruker Autoﬂex I MALDI TOF mass spectrometer) to
identify the strain, as described.2 We obtained a spectrum with no
reliable identiﬁcation: scores were higher than 2 (up to 2.22) for
both Y. pseudotuberculosis and Y. pestis. Finally, a positive urease test
(different from the one present in API1systems) yielded a deﬁnitive
identiﬁcation of Y. pseudotuberculosis, which was further conﬁrmed
by the French national reference center, and the isolate wasassigned as Y. pseudotuberculosis serotype I using a serotyping
scheme based on O-antigen.
To evaluate the pathogenicity of this isolate, the presence of the
three key virulence factors (the T3SS encoding virulence plasmid
pCD1 (70 kb), the High Pathogenicity Island (HPI), and YPM
superantigens) were investigated. The pCD1 plasmid required for
pathogenicity was detected by DNA ampliﬁcation of both the
entire lcrV and yopH genes using the sets of primers [50-
TCACCGCGCAAAATTATTGC (forward) and 50-TTGTCTGCGA-
TAAGCTCTTG (reverse)] and [50-TTGGTGCAGCAAGAGAGCG (for-
ward) and 50-CCAGTGAAGCGAGTGCCTTG (reverse)], respectively.
The presence of HPI carrying the yersiniabactin (Ybt) system is
correlated with the level of pathogenicity3 and was determined by
PCR with primers located in 3 distinct genes: ybtA [50-CACCG-
CAAACGCAATCTGAAA (forward) and 50-AAATGGCTGGCGTTGGCA-
TAG (reverse)], ybtX [50-GGGGTTTCCGCGTCTGGAGA (forward) and
50-ATGTCGCCTGCGTTCCGTCG (reverse)] and fyuA [50-ATTCAG-
GATGGCCTGCTG (forward) and 50-GACGATTAACGAACCGGA (re-
verse)], encoding AraC-transcriptional activator, a protein with
unknown function and the outer membrane receptor of the Fe-
yersiniabactin, respectively. All three genes were absent form this
strain, thus suggesting a spontaneous excision of HPI.4 Therefore,
the possible presence of endogenous plasmid pGDT4 ( 100 kb)
involved in the autoexcision of the HPI was screened by PCR5 in
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pGDT4 was not detected. The Ybt system appeared not to be
essential for the Y. pseudotuberculosis strain isolated from our
patient, partly because there are multiple additional iron capture
systems operating in Yersinia capable of giving a similar
phenotype.6 However, the iron-overload diagnosed in our patient
may provide a better explanation for the absence of Ybt since iron-
overloaded is known to restore or increase the virulence of Ybt-
negative Yersinia.7 Then, the three variants of Ypm superantigens
(ypmA, ypmB and ypmC) were searched directly in the strain using
PCR technique with the following primers: ypmA1:C1/ypmA2:C2,
ACACTTTCCTCTGGAGTA(GCG/ACA)GGACATTTCGTCA, and ypmB1/
ypmB2, CTAATCCCCCGAGGATAA(GTT/GGC)GATTCCGACGACATA-
TAAC.8 As expected according to clinical symptoms, this strain of Y.
pseudotuberculosis did not produce the superantigenic toxin YPM
which seems to be involved in microvascular disease such as
Kawasaki syndrome9 rather than bacteremia. Lastly, detection of
type IV pilus locus that has been described in some strains of Y.
pseudotuberculosis as a possible virulence factor associated with
bacterial colonization of the intestinal mucosa was screened by
PCR with 3 primers amplifying pilN, pilS and pilQ.10 No ampliﬁca-
tion products were obtained with the three primer sets. These
results indicated that this strain did not harbour the type IV pilus
gene cluster.
Antibiotic susceptibility testing by disk diffusion method11 was
characterized by a full susceptibility to beta-lactams, quinolones
and aminoglycosides. The results of antimicrobial susceptibility
testing were transmitted to clinicians on D7 (Table 1). Considering
the lack of clinical improvement, amoxicillin/clavulanic acid was
changed to third-generation cephalosporin. However, clinical
evolution was unfavorable under conditions of treatment with
ciproﬂoxacin and third-generation cephalosporin. Thus, the
patient received two once-daily dose of gentamicin. Ciproﬂoxacin
therapy was stopped on D12 because of favorable clinical outcome,
while third-generation cephalosporin was pursued until D18 for a
total of nine days of treatment (Table 1).
2. Discussion
Y. pseudotuberculosis is a Gram negative coccobacillus that
grows optimally at cooler temperatures, and a zoonotic organism
of worldwide distribution with reservoirs in rodents, birds and
mammals that causes formation of purulent, caseous abscesses of
the lymph nodes, liver and spleen.12–16 Transmission to humans is
uncommon and occurs through ingestion of contaminated food,
water or milk, or direct contact with an infected animal.16,17
Y. pseudotuberculosis infections typically manifest within a
mesenteric lymphadenitis accompanied by abdominal pain and
fever and less often vomiting and diarrhea; it is most often
detected in children and adolescents and may be indistinguishable
from acute appendicitis.16 Bacteremia due to Y. pseudotuberculosis
rarely occurs,13 but they have been described in patients with an
underlying disorder such as hepatic cirrhosis, hemochromatosis,
hepatitis or diabetes; in particular, iron overload has been
suggested to be a predisposing factor for systemic Y. pseudotuber-
culosis infection,13,16 such as was the case for our cirrhotic patient
who presented with hemophagocytic syndrome. Isolation of Y.
pseudotuberculosis from ascitic ﬂuid samples or from peritoneal
ﬂuid samples has been rarely reported, since only four cases were
recovered in the literature.18–21 Y. pseudotuberculosis can be
recovered in the ascitic or peritoneal ﬂuids or cause bacteremia
in cirrhotic patients because bowel bacteria are likely to escape the
bacterial ﬁlter in the liver, since (i) a high proportion of the portal
ﬂow may bypass the liver sinusoids and (ii) the local and systemic
immune functions are altered in cirrhotic patients.Delayed diagnosis was likely consecutive to difﬁculty
associated with culturing Yersiniae on standard media. The
patient began to recover 24 hours after the initiation of an
antimicrobial chemotherapy with a third-generation cephalo-
sporin combined with gentamicin while a treatment by
ﬂuoroquinolone alone failed to cure the Y. pseudotuberculosis
infection (Table 1), thus contrasting with results obtained in
murine model of yersiniosis. Indeed, ﬂuoroquinolone therapy
has shown to be particularly effective in a murine model of
yersiniosis and has been used successfully for Yersinia infections
in several cases while beta lactams therapy is associated with
lower survival in mice or poor clinical response. 22,23 A poor
clinical response to ﬂuoroquinolone alone and favorable issue
after introduction of an aminoglycoside to quickly control
infection in immunocompromised patients has been previously
described in a diabetic patient.13 Mortality rate associated with
Y. pseudotuberculosis bacteremia has been reported as high as
75% despite antibiotic treatment in patients with underlying
conditions, thus emphasizing the need for rapid bactericidal
antimicrobial chemotherapy in immunocompromised patients
with comorbidities.13 Finally, a rapid synergistic bactericidal
antimicrobial chemotherapy against Gram negative bacillary
infection may be better obtained with a combination of third-
generation cephalosporin and aminoglycoside than ﬂuoroquin-
olone alone in such patients. It is therefore questioned which
molecules or antibiotic combinations are the most effective
treatment of lethal invasive Y. pseudotuberculosis infections.
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